Captisol enabled therapeutic - Interventional Analgesix
Latest Information Update: 28 Apr 2022
At a glance
- Originator Interventional AnalgesiX
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Unspecified in USA
- 16 Mar 2018 Preclinical trials in Unspecified in USA (Ligand Pharmaceuticals pipeline, March 2018)
- 22 May 2017 Interventional AnalgesiX in-licenses the Captisol® technology from Ligand Pharmaceuticals